Zobrazeno 1 - 10
of 252
pro vyhledávání: '"Antonio Llombart-Cussac"'
Autor:
Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102520- (2024)
Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advan
Externí odkaz:
https://doaj.org/article/c5ba8bd9a6864624b463e00529accd71
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Juan Carlos Andreu-Ballester, Lorena Galindo-Regal, Carmen Cuéllar, Francisca López-Chuliá, Carlos García-Ballesteros, Leonor Fernández-Murga, Antonio Llombart-Cussac, María Victoria Domínguez-Márquez
Publikováno v:
Vaccines, Vol 12, Iss 5, p 553 (2024)
Background: The COVID-19 pandemic is the biggest global health problem in the last hundred years. The efficacy of the vaccine to protect against severe disease is estimated to be 70–95% according to the studies carried out, although there are aspec
Externí odkaz:
https://doaj.org/article/01cf6345879c4709ba3f6415040f19f6
Autor:
Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, Mark Pegram, Lajos Pusztai, Nicholas Turner, Giuseppe Viale
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient’s optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including multigene ass
Externí odkaz:
https://doaj.org/article/12116133d8ab4ea984c661474f340f2b
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, Elena López-Miranda, María Gion, Elena Abad, Daniel Alcalá-López, Jhudit Pérez-Escuredo, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate de-intensified regimens with si
Externí odkaz:
https://doaj.org/article/4129d5abe3b54a4aa1163a0967a18f28
Autor:
Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
International Journal of Infectious Diseases, Vol 123, Iss , Pp 97-103 (2022)
Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- inter
Externí odkaz:
https://doaj.org/article/03300a66cee940b7bc9b769d46d85504
Publikováno v:
Pathogens, Vol 12, Iss 9, p 1086 (2023)
Breast cancer (BC) is the most frequently occurring malignancy and the second cancer-specific cause of mortality in women in developed countries. Over 70% of the total number of BCs are hormone receptor-positive (HR+), and elevated levels of circulat
Externí odkaz:
https://doaj.org/article/8885ba0c899042dd8162c09654f7f099
Autor:
Tomás Pascual, Mafalda Oliveira, Patricia Villagrasa, Vanesa Ortega, Laia Paré, Begoña Bermejo, Serafín Morales, Kepa Amillano, Rafael López, Patricia Galván, Jordi Canes, Fernando Salvador, Paolo Nuciforo, Isabel T. Rubio, Antonio Llombart-Cussac, Serena Di Cosimo, José Baselga, Nadia Harbeck, Aleix Prat, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Eribulin prolongs overall survival in patients with pre-treated advanced breast cancer. However, no biomarker exists to prospectively select patients who will benefit the most from this drug. SOLTI-1007-NeoEribulin is a phase II, open-label,
Externí odkaz:
https://doaj.org/article/41c7b00b4fff4204abca055bdf4c6649
Autor:
Miguel Gil-Gil, Emilio Alba, Joaquín Gavilá, Juan de la Haba-Rodríguez, Eva Ciruelos, Pablo Tolosa, Daniele Candini, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 58, Iss , Pp 160-169 (2021)
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading
Externí odkaz:
https://doaj.org/article/b91e8dfa159f483185c1f1ac86ed4294
Autor:
Antonio Llombart-Cussac, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A. Rodríguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, María Leonor Fernández-Murga, Carlos Hagen, Manuel Ruiz-Borrego
Publikováno v:
Cancers, Vol 15, Iss 5, p 1529 (2023)
Background: The 21-gene Oncotype DX Breast Recurrence Score® assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, HER2− early breast cancer (EBC). The KARMA Dx study evaluated the impact of the R
Externí odkaz:
https://doaj.org/article/46d86c99bc9349a4a7ae93ce87436f64